4min chapter

Oncology Today with Dr Neil Love cover image

Novel Agents and Strategies in Lung Cancer

Oncology Today with Dr Neil Love

CHAPTER

Tarlatumab Approval: Insights from the Delphi 301 Study

This chapter covers the recent approval of Tarlatumab, a bispecific T cell engager, focusing on its clinical trial results from the Delphi 301 study. With a reported response rate of 40% and critical metrics like duration of response and median overall survival, the chapter also examines the dosing strategies and comparisons within the trial.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode